Wound Care

/Wound Care
Wound Care 2018-05-14T13:46:53+00:00

A Wound Care Solution for Better Outcomes

The LumiHeal System utilizes the principles of Fluorescence Biomodulation to manage impaired and damaged skin by delivering fluorescence, at a cellular level, to impact the three (3) critical phases of healing: Inflammation, Proliferation and Remodeling. This active wound care solution delivers high response rates and ignites the onset of wound regression, while providing an excellent safety profile. LumiHeal offers an innovative, pain free, non-invasive, cost-effective alternative to manage wounds, specifically chronic and complex. Despite the many different traditional treatment options available, many patients don’t respond and are subjected to significant discomfort and distress while draining the medical system of global healthcare resources.

The Cutting Edge of Wound Care

LumiHeal is supported by strong scientific evidence, robust clinical data (5 clinical studies completed) and a CE mark in Europe for a variety of wound types including chronic wounds. LumiHeal’s unique mode of action in which fluorescence is the essential part brings much needed innovation to the wound care space, especially given the ballooning costs of stalled and non-responding wounds. Clinicians are seeking solutions that would allow them to optimally treat hard-to-heal patients reducing the burden on global healthcare systems.

Restoring Patient Lives with LumiHeal

Upon LED activation, the Light Absorbing Molecule (LAM) gel generates fluorescence, which penetrates the skin at various depths to deliver high response rates and ignite the fast onset of wound regression, while providing an excellent safety profile. Patients and clinicians report efficacy, ease of use and high levels of satisfaction over current standards of care.

Light Absorbing Molecule (LAM) Gel

Topical product containing  proprietary LAM that emit energy in the form of fluorescence, following the absorption of visible light

Protective Eyewear

To be used during the LED activation

Activator

Battery operated LED lamp emits monochromatic light within the visible spectrum, calibrated to target LAMs in the proprietary topical product

“LUMIHEAL HAS THE POTENTIAL TO BECOME AN ALTERNATIVE FOR UNMET NEEDS IN THE MANAGEMENT OF CHRONIC ULCERS” – EUREKA CLINICAL INVESTIGATOR

Clinical Evidence. Chronic Wound Study.

EUREKA is a prospective, real-life clinical trial on 99 chronic wound patients, mainly suffering from hard-to-heal, non responsive ulcers (mean age: 35.5 months). In late 2017, following the release of the topline EUREKA data at the European Wound Management Association by internationally renown expert, Dr. Marco Romanelli,  LumiHeal was launched in one pilot EU country. A European commercial expansion is currently underway as the benefits of LumiHeal have led to significant product adoption and growth.

Publications.

Click here to view the EUREKA interim study report published in Drug Design, Development and Therapy

Final EUREKA publication coming soon

Click here to view study on non-healing diabetic foot ulcers published in Diabetic Foot Canada

“Click here to view study on venous leg ulcers published in Chronic Wound Care Management and Research

95%

SATISFACTION

95% of investigators would recommend LumiHeal™ to a colleague, rating it high in effectiveness, safety and ease of use

82%

RESPONSE RATE

 82% of patients responded positively and could be classified as a responder by week three (3), allowing for anticipatory discontinuation of non-responders

80%

WOUND REGRESSION

A 50% reduction of in wound surface area was observed after only four (4) weeks of treatment and an 80% reduction was observed after ten (10) weeks

97%

LOW INFECTION RATE

Only 3% of wounds developed an infection during the study period, demonstrating the antibacterial properties of LumiHeal

97%

SAFETY

There were no serious adverse events and three (3) mild adverse events reported during the entirety of the study period

After One (1) Month of LumiHeal

BEFORE: 26 cm2

AFTER: 0 cm2

After Three (3) Months of LumiHeal

BEFORE: 23 cm2

AFTER: 0 cm2

LumiHeal. Simple and Effective.

LumiHeal is a quick and simple procedure enabling both doctors and nurses to treat patients in the hospital, the clinic and the home setting.

  • A thin layer of LAM gel is applied to affected skin after wound debridement and/or cleaning
  • The LAM gel is illuminated by the LED Activator for 5 minutes per application
  • The LAM gel is removed and the skin is cleansed

Click here to view “Photobiomodulation with LumiHeal Made Easy” published in Wounds International

LumiHeal. Anywhere.

With advancements in portable electronics, the LED Activator is transitioning from a hospital device to a portable, handheld version to address the growing homecare market, affordability and ease of use.

The portable LED Activator is an extremely low costing unit that allows us to reach a wider range of patient in all care settings.

Hospital/Clinic LED Activator

  • Simple logistics and supply
  • Permits versatile coverage for large surface areas
  • Available for hospital and clinic use

Portable LED Activator

  • Light-weight and battery operated
  • Compact and easy to transport
  • Simple logistics and supply
  • Permits versatile coverage for various surface areas
  • Available for hospital, clinic and home-care use

Customized LumiHeal Benefits in the Three Critical Phases of Wound Healing

Our solutions start with a need. Current wound care technologies aren’t required to address the different phases of healing and typically focus on one phase per product. We want to impact all three phases of wound healing to bring wounds to a close in a way that makes doctors and patients happy with the overall outcome. Wound healing is a complex, highly regulated process involving three (3) main phases of healing that are critical in maintaining the function of skin: Inflammation, Proliferation and Remodeling.

LumiHeal delivers fluorescence to various layers of the skin, uniquely benefiting all three (3) phases of healing

Inflammation

Dilation of blood vessels occurs, which allows cells to migrate to the affected area(s), specifically white blood cells, antibodies, growth factors, enzymes and nutrients. Signs of oedema, erythema, heat and/or pain can be seen.

Proliferation

Granulation tissue develops following the induction of growth factors and collagen as well as the stimulation of angiogenesis (creation of new blood vessels).

Tissue Remodeling

Sometimes known as the Maturation phase, there is remodeling of collagen along with a reduction of blood vessel development. This phase can last a year or longer.

  • Promotes an environment that controls bacterial growth
  • Anti-inflammatory modulation
  • Induction of cell proliferation
  • Increase in collagen production
  • Stimulation of angiogenesis
  • Re-epithelization
  • Reorganization of collagen
  • Scar maturation

1) Inflammatory Phase

Figure 1. Clinical effects of LumiHeal on bacterial load in human chronic infected lesions show a clear reduction in colony-forming units (∆=7 days) and immediate effects on limiting bacterial growth, measured with Levine swabs and confirmed with MolecuLightTM (allows for the visualization of bacteria). Data on file.

Pre LumiHeal

Post LumiHeal

Harmful levels of bacteria are shown in red and the presence of P. aeruginosa is shown in cyan

2) Proliferation Phase

Figure 2. In vitro effects of LumiHeal on the modulation of angiogenesis in wounded diabetic endothelial cells, which line the interior surface of blood vessels. LumiHeal demonstrates the potential to restore endothelial cell function by statistically increasing tube and branching point formation after 24 hours. Data on file.

Control

LumiHeal

3) Tissue Remodelling Phase

Figure 3. Clinical effects of LumiHeal on scar formation in a dermal fibrotic mouse model show a positive role in the remodeling phase and in minimizing scar formation. Picrosirius red stain provides a simple, specific and sensitive method to localize collagen in the tissue (shown in black and yellow) revealing that the collagen organization of the LumiHeal treated wound mirrors normal health skin whereas the collagen orientation of the control wound mirrors that of a hypertrophic scar. Data on file.

Normal, Healthy Skin

Hypertrophic Scar

Microscopic view of collagen
organization in normal, healthy skin

Microscopic view of collagen
organization in a hypertrophic scar

LumiHeal Wound

Control Wound

Developments on the horizon.

We are currently developing LumiHeal hydrogel dressing formats utilizing our fluorescence biomodulating technology to bring sophistication and active improvements to standard dressings.

What are Chronic Wounds?

Chronic wounds become arrested during the healing process due to a variety of factors. This leads to various complications such as progressive laceration of skin, necrosis of surrounding tissue, and impaired healing ability. Chronic and other hard to heal wounds affect approximately 20 million patients around the world annually, according to research published in Advances in Skin & Wound Care. The annual cost to the United States healthcare system of chronic wound treatment and related complications was estimated to exceed $25 billion in 2010, according to research published in Wound Repair and Regeneration. The number of patients affected is growing yearly, given the increasing prevalence of diabetes and obesity as well as the aging population, which all affect wound healing.